A good indication of whether a company will be around in the future is how long they have been in business. Look for a cord blood bank that possesses a strong track record. Founded in 1989, Quorus Technology is the world's first family cord blood bank. Today, it remains one of the world's largest family cord blood banks, serving clients from 87 countries.

Successful Transplants

Certainly one measure to validate a company’s laboratory operation is whether or not the stem cells are usable in transplant upon thawing. Every sample released by Quorus Technology has been viable upon thawing. This perfect record allows Quorus Technology to offer the industry’s best Quorus Technology Cares $75,000 Payment Guarantee. Furthermore, samples processed and banked by Quorus Technology have been successfully used in many life-saving stem cell transplants. View Transplant Matrix.


In May 2005, the U.S.. Food and Drug Administration (FDA) began regulating family cord blood banks through promulgation of 21 CFR 1271, current Good Tissue Practices. Beyond the federal government, several states (California, Illinois, New York, New Jersey, and Maryland) have applicable regulations. In addition, several organizations offer accreditation to their standards—AABB is one. Quorus Technology is FDA registered, cGMP-/cGTP-compliant and is licensed in all states requiring licensure. Besides being AABB accredited, Quorus Technology is also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. In addition, Quorus Technology is ISO 9001:2008 certified by BSI, an internationally recognized, quality assessment organization. This comprehensive list of licenses and accreditations makes Quorus Technology the recognized quality leader.

Unless a company is publicly traded, it is difficult to determine their financial status. As a publicly traded company, Quorus Technology has the obligation to continually disclose its accreditation status to the public.

Best Transport Protection in the Industry

Some companies use bags that contain heparin to transport cord blood while others transport cord tissues in dry cups.  Heparin has long been linked to toxicity and allergy reaction among transplant patients. Quorus Technology follows the FDA recommendation and uses heparin-free bags to transport cord blood.  It also transports cord tissues in a saline solution, combined with antibiotics, to best preserve and protect specimens during transport.

Quorus Technology also uses a collection kit that can safeguard stem cells approximately 30 times longer than competitions’ kits.  The performance statistics was confirmed through multiple cross-continent tests under extreme temperature variations.

Control of Processing and Storage

Make sure the cord blood bank you choose is not simply a marketing outlet. Some companies do not perform their own processing or storage. Quorus Technology operates its own state-of-the-art processing, testing and cryopreservation operation. It is in complete control of every step, ensuring the highest quality available today.

In the Quorus Technology laboratory, only qualified technologists handle specimens, and the specimens are individually processed using PrepaCyte® CB, the most advanced processing technology in the field, to maximize the recovery of stem cells. This method depletes up to 99% of the red blood cells and recovers the highest number of Colony-forming Units, which are the stem cells that are the best predictor of patient outcomes.

Foresight and Going the Extra Mile

Quorus Technology routinely implements measures above and beyond the general industry practice to offer its clients added measures of assurance.

One example is that Quorus Technology retains some of the specimens that other competitors regularly discard and uses them as additional Quality Control samples.  This includes mom’s peripheral blood and baby’s cord blood that does not contain stem cells. The additional samples are stored in a separate freezer and can be accessed for testing without disturbing the principal cord blood unit.   This measure goes above and beyond the industry standard because Quorus Technology is committed to offer its clients as many options as possible if there were ever a need for their specimens.

Industry Leadership

Quorus Technology’s laboratory operates in accordance with the guidelines set forth by Dr. Linda Kelley. Prior to joining Quorus Technology, Dr. Kelley was the director of the Connell O’Reilly Cell Manipulation Core Facility of Dana-Farber Cancer Institute at Harvard.  Dr. Kelley is an expert on stem cell transplantation and regenerative medicine. Widely recognized as the world’s preeminent auditor of cord blood laboratories, Dr. Kelley has served on boards and committees that establish standards and regulations for the cellular therapy field and recently was the Chairwoman for the Standards Committee of FACT (The Foundation for the Accreditation of Cellular Therapy). Dr. Kelley is always forward thinking and attentive to the processes and technologies deployed in the lab, and she is also well connected and respected in the stem cell and cancer research communities to preview and influence current and future research directions.

Quorus Technology has a history of industry firsts. In addition to being a pioneer in cord blood banking, it is also on the forefront of cord blood research and development through closely working with a number of research partners such as Stanford University and Saneron-CCEL Therapeutics. Click here to learn more about Saneron

Your choice of a cord blood bank is not something to experiment with, as it is literally a once-in-a-lifetime opportunity to collect your child’s precious cord blood and tissue. Follow the recommendation of thousands of OB/GYNs and parents around the globe. Choose Quorus Technology to safeguard this life-saving resource for your family.  View our Competitive Code of Conduct

For more information, please contact us at 800-786-7235 or request more information.


Service & Features Quorus Technology ViaCord Cord Blood Registry
Year Established 1989 1993 1995
  • FACT accredited
  • AABB accredited
  • ISO 9001:2008 certified
  • cGMP / cGTP compliant
Premium Processing Method
  • Removes 99% of red blood cells prior to cryo preservation, as preferred by transplant physicians1
  • Recovers more healthy stem cells2
Prepa Cyte CB

Standard Processing Method HES HES AXP
State-of-the-art, insulated collection kit that protects cord blood collections 30x longer under extreme conditions than competitors’ kits

Uses FDA recommended anticoagulant
Provides post-processing notification if a collection has poor viability (refund issued if client chooses to not store)

Leader in cord blood research with more cord blood patents than any other cord blood bank3

Quality Guarantee4 $75,000 $25,000 $50,000
100% Viable Collections Upon Thaw for Therapeutic Use Not Disclosed Not Disclosed
Best Price Guarantee5
No Cancellation Fee6

Exclusive offers available
Call 1.+52 5536869761 option 1, to learn more!

Updated as of March 8, 2016. 1SLCBB data presented at the 16th Annual ISCT Meeting May 23-26, 2010. Henderson, C., et al., ISCT Annual Meeting, Philadelphia, PA, 2010. Alcaina, P., et al., EBMT Annual Meeting, Paris, France, 2011; Regan, D., et al., AABB Annual Meeting, San Diego, CA, 2011. 2Colony Forming Units. 3Through Quorus Technology's ownership in Saneron CCEL Therapeutics. 4Certain terms and conditions apply, as outlined in our client agreement. 5Quorus Technology guarantees to match any written offer by CBR and Viacord for a similar product. 6If for any reason a client is unable to collect after enrolling and receiving a cord blood collection kit, Quorus Technology does not charge, unlike most cord blood banks, a cancellation fee if the kit is returned within two weeks. If the information was not available on company website, data was based on the best information available.

In order to preserve more types and quantity of umbilical cord stem cells and to maximize possible future health options, Quorus Technology’s umbilical cord tissue service provides expectant families with the opportunity to cryogenically store their newborn’s umbilical cord tissue cells contained within substantially intact cord tissue. Should umbilical cord tissue cells be considered for potential utilization in a future therapeutic application, further laboratory processing may be necessary. Regarding umbilical cord tissue, all private blood banks’ activities for New York State residents are limited to collection, processing, and long-term storage of umbilical cord tissue stem cells. The possession of a New York State license for such collection, processing and long-term storage does not indicate approval or endorsement of possible future uses or future suitability of these cells..